iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.5450
-0.0300 (-5.22%)
Sep 18, 2026, 5:10 PM SGT
iX Biopharma Ratios and Metrics
Market cap in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Market Capitalization | 594 | 390 | 14 | 22 | 70 | 122 |
Market Cap Growth | 3418.43% | 2644.34% | -36.24% | -68.05% | -43.05% | -26.84% |
Enterprise Value | 585 | 379 | 17 | 22 | 62 | 111 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PS Ratio | 86.62 | 56.89 | 1.83 | 3.74 | 11.79 | 8.51 |
PB Ratio | 38.56 | 25.33 | 38.92 | 5.13 | 4.40 | 6.20 |
P/TBV Ratio | 38.56 | 25.33 | 149.55 | 5.51 | 4.48 | 6.31 |
P/FCF Ratio | - | - | - | - | - | 41.89 |
P/OCF Ratio | - | - | - | - | - | 39.21 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 85.32 | 55.35 | 2.20 | 3.73 | 10.51 | 7.70 |
EV/EBITDA Ratio | - | - | - | - | - | 96.40 |
EV/EBIT Ratio | - | - | - | - | - | 221.09 |
EV/FCF Ratio | - | - | - | - | - | 37.89 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.38 | 0.38 | 16.17 | 1.20 | 0.27 | 0.22 |
Debt / EBITDA Ratio | - | - | - | - | - | 2.91 |
Debt / FCF Ratio | - | - | - | - | - | 1.51 |
Net Debt / Equity Ratio | -0.58 | -0.58 | 13.61 | 0.77 | -0.14 | -0.46 |
Net Debt / EBITDA Ratio | 0.97 | 0.97 | -0.85 | -0.47 | 0.24 | -7.99 |
Net Debt / FCF Ratio | 1.17 | 1.17 | -1.25 | -0.49 | 0.26 | -3.14 |
Asset Turnover | 0.37 | 0.37 | 0.60 | 0.30 | 0.22 | 0.61 |
Inventory Turnover | 4.18 | 4.18 | 4.98 | 4.21 | 3.86 | 2.09 |
Quick Ratio | 1.67 | 1.67 | 0.32 | 0.65 | 1.34 | 1.98 |
Current Ratio | 1.86 | 1.86 | 0.47 | 0.89 | 1.53 | 2.14 |
Return on Equity (ROE) | -101.43% | -101.43% | -431.07% | -106.91% | -54.02% | -29.23% |
Return on Assets (ROA) | -32.16% | -32.16% | -30.32% | -23.69% | -22.32% | 1.32% |
Return on Capital Employed (ROCE) | -60.20% | -60.20% | -272.70% | -103.50% | -53.80% | 2.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | -1.35% | -2.05% | -71.38% | -48.44% | -13.79% | -3.75% |
FCF Yield | -1.28% | -1.96% | -27.87% | -30.64% | -11.98% | 2.39% |
Buyback Yield / Dilution | -10.07% | -10.08% | -14.25% | -0.33% | -2.51% | -7.60% |